-

Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the first quarter of 2020 on Thursday, May 7, 2020. During a conference call at 8:30 a.m. ET on May 7, 2020, company executives will review financial information and address inquiries from analysts.

Investors and the general public are invited to listen to a live webcast of the call at bms.com/investors or by dialing in the U.S. toll free 888-256-1007 or international 1-786-789-4797, confirmation code: 3261903. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 12 p.m. ET on May 7 through 12 p.m. ET on May 21, 2020. The replay will also be available through bms.com/investors or by dialing in the U.S. toll free 888-203-1112 or international 1-719-457-0820, confirmation code: 3261903.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contacts

Bristol Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

Bristol-Myers Squibb Company

NYSE:BMY

Release Summary
Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020
Release Versions
$Cashtags

Contacts

Bristol Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

More News From Bristol-Myers Squibb Company

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung......

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

BOTHELL, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)--Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2-......
Back to Newsroom